Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Clinical trial NCT05980000 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05980000
Sponsor: Washington University School of Medicine
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Head and Neck Cancer Recurrent Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Carcinoma Metastatic Head-and-neck Squamous-cell Carcinoma Metastatic Head and Neck Cancer HNSCC

Start date: 2023-10-27
Primary completion: 2027-06-30
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.